On February 25, 2025, the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older." Following the CDC's announcement and subsequent reporting by media outlets, Valneva's American Depositary Receipt ("ADR") price fell $1.06 per ADR, or 13.57%, over the following four ...